170 results on '"Gidaro, A"'
Search Results
2. Letter in response to a recent article by Zhang et al.[1]
3. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping
4. The administration of methotrexate in patients with Still's disease, “real-life” findings from AIDA Network Still Disease Registry
5. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping
6. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
7. The Administration of Methotrexate in Patients with Still's Disease, 'Real-Life' Findings from Aida Network Still Disease Registry
8. P.110 JEWELFISH: 24-month safety and pharmacodynamic data in non-treatment-naïve patients with spinal muscular atrophy (SMA)
9. Circulating endothelial progenitors are increased in COVID‐19 patients and correlate with SARS‐CoV‐2 RNA in severe cases
10. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
11. Extraperitoneal Radical Prostatectomy with the Senhance Robotic Platform: First 40 Cases
12. P.110 JEWELFISH: 24-month safety and pharmacodynamic data in non-treatment-naïve patients with spinal muscular atrophy (SMA)
13. CLINICAL RESEARCH
14. Life expectancy in Italian patients with hereditary angioedema due to C1-inhibitor deficiency
15. Rimeporide as a first- in-class NHE-1 inhibitor : Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy
16. Extraperitoneal Radical Prostatectomy with the Senhance Robotic Platform: First 40 Cases
17. CLINICAL RESEARCH
18. DMD – BIOMARKERS & OUTCOME MEASURES
19. Circulating endothelial progenitors are increased in COVID‐19 patients and correlate with SARS‐CoV‐2 RNA in severe cases
20. Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy
21. Life expectancy in Italian patients with hereditary angioedema due to C1-inhibitor deficiency
22. DMD – BIOMARKERS & OUTCOME MEASURES
23. MRI – MUSCLE IMAGING
24. P.107Clinical changes over time in patients with centronuclear myopathy due to mutations in DNM2 gene enrolled in a European prospective natural history study
25. P.240ASC-1 related myopathy: phenotypic spectrum and pathophysiology of an emerging congenital myopathy
26. P.107Clinical changes over time in patients with centronuclear myopathy due to mutations in DNM2 gene enrolled in a European prospective natural history study
27. P.200Feasibility and baseline values of continuous movement measurement in patients with centronuclear myopathy by using ActiMyo®
28. P.240ASC-1 related myopathy: phenotypic spectrum and pathophysiology of an emerging congenital myopathy
29. O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial
30. P.191Maximal stride velocity detects positive and negative changes over 6- month-time period in ambulant patients with Duchenne muscular dystrophy
31. OUTCOME MEASURES
32. MRI – MUSCLE IMAGING
33. Short term prophylaxis in patients with hereditary angioedema undergoing dental procedures
34. Two Cases Of Peculiar Hypereosinophilic Syndrome Treated With Mepolizumab
35. Clinical Features of Patients With Primary Angioedema With Normal Levels of C1-Inhibitor
36. Telelap Alf-X–Assisted Laparoscopy for Ovarian Cyst Enucleation: Report of the First 10 Cases
37. Congenital muscular dystrophy phenotype with neuromuscular spindles excess in a 5-year-old girl caused by HRAS mutation
38. Continuous Venovenous Hemofiltration After Coronary Procedures for the Prevention of Contrast-Induced Acute Kidney Injury in Patients With Severe Chronic Renal Failure
39. SMA THERAPIES I
40. O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial
41. OUTCOME MEASURES
42. Two Cases Of Peculiar Hypereosinophilic Syndrome Treated With Mepolizumab
43. Short term prophylaxis in patients with hereditary angioedema undergoing dental procedures
44. Clinical Features of Patients With Primary Angioedema With Normal Levels of C1-Inhibitor
45. DUCHENNE MUSCULAR DYSTROPHY - PHYSIOTHERAPY
46. DUCHENNE MUSCULAR DYSTROPHY - PHYSIOTHERAPY
47. CONGENITAL MYASTHENIC SYNDROMES AND MYASTHENIA
48. REGISTRIES AND CARE OF NEUROMUSCULAR DISORDERS
49. SMA CLINICAL DATA, OUTCOME MEASURES AND REGISTRIES
50. PSY89 - COSTS AND EFFECTS OF ON-DEMAND TREATMENT OF HEREDITARY ANGIOEDEMA: A PROSPECTIVE COHORT STUDY IN ITALY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.